Figures & data
Table 1 Patient characteristics of the whole sample (n=1,111)
Figure 1 Patient primary-care institutions.
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
Table 2 Patient characteristics according to GOLD 2014 groups
Figure 2 Distribution of patients by GOLD 2013 group.
Notes: GOLD A (low risk, fewer symptoms), GOLD B (low risk, more symptoms), GOLD C (high risk, fewer symptoms), or GOLD D (high risk, more symptoms). Patients in groups C and D were stratified into three subgroups as C1, C2, and C3, and D1, D2, and D3 based on the specific risk factor used to determine the group assignment: C1 or D1 (FEV1 <50%), C2 or D2 (two or more exacerbations or one hospitalization), and C3 or D3 (both FEV1 <50% and two or more exacerbations or one hospitalization within the last year).
Abbreviation: GOLD, Global Initiative for Chronic Obstructive Lung Disease.
Abbreviation: GOLD, Global Initiative for Chronic Obstructive Lung Disease.
Table 3 Patient characteristics according to clinical phenotypes
Figure 3 Distribution of patients by clinical phenotype.
Abbreviation: ACO, asthma–COPD overlap.
Figure 4 (A) Treatment patterns by GOLD 2014 B and D; (B) treatment patterns by GOLD D subgroups.
Notes: GOLD B (low risk, more symptoms), GOLD D (high risk, more symptoms). Patients in group D were stratified into three subgroups as D1, D2, and D3 based on the specific risk factor used to determine the group assignment: D1 (FEV1 <50%), D2 (two or more exacerbations or one hospitalization), and D3 (both FEV1 <50% and two or more exacerbations or one hospitalization within the last year).
Abbreviations: SABD, short-acting bronchodilator; LAMA, long-acting muscarinic antagonist; LABA, long-acting β2-agonist; ICS, inhaled corticosteroid; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
Abbreviations: SABD, short-acting bronchodilator; LAMA, long-acting muscarinic antagonist; LABA, long-acting β2-agonist; ICS, inhaled corticosteroid; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
